A follow-up study of the prevalence of valvular heart abnormalities in hyperprolactinemic patients treated with cabergoline by Drake, William M et al.
 
 
A follow-up study of the prevalence of valvular heart
abnormalities in hyperprolactinemic patients treated
with cabergoline
Drake, William M; Stiles, Craig E; Bevan, John S; Karavitaki, Niki; Trainer, Peter J; Rees, D
Aled; Richardson, Tristan I; Baldeweg, Stephanie E; Stojanovic, Nemanja; Murray, Robert D;
Toogood, Andrew; Martin, Niamh M; Vaidya, Bijay; Han, Than S; Steeds, Richard; Baldeweg,
F C; Sheikh, U E; Kyriakakis, N; Parasuraman, S K; Butt, N
DOI:
10.1210/jc.2016-2224
License:
None: All rights reserved
Document Version
Peer reviewed version
Citation for published version (Harvard):
Drake, WM, Stiles, CE, Bevan, JS, Karavitaki, N, Trainer, PJ, Rees, DA, Richardson, TI, Baldeweg, SE,
Stojanovic, N, Murray, RD, Toogood, AA, Martin, NM, Vaidya, B, Han, TS, Steeds, R, Baldeweg, FC, Sheikh,
UE, Kyriakakis, N, Parasuraman, SK, Butt, N & UK Cabergoline valvulopathy study group 2016, 'A follow-up
study of the prevalence of valvular heart abnormalities in hyperprolactinemic patients treated with cabergoline',
Journal of Clinical Endocrinology and Metabolism, vol. 101, no. 11, pp. 4189-4194.
https://doi.org/10.1210/jc.2016-2224
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Eligibility for repository: Checked on 6/9/2016
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
A follow-up study of the prevalence of valvular heart
abnormalities in hyperprolactinemic patients treated
with cabergoline
WM Drake1, CE Stiles1, JS Bevan2, N Karavitaki3, PJ Trainer4, DA Rees5,
TI Richardson6, SE Baldeweg7, N Stojanovic8, RD Murray9, AA Toogood10,
NM Martin11, B Vaidya12, TS Han13,
RP Steeds14, On behalf of the UK Cabergoline valvulopathy study group*,
*FC Baldeweg7, UE Sheikh12, N Kyriakakis9, S Parasuraman2, L Taylor14, N Butt6,
S Anyiam4
1. Dept Endocrinology, St Bartholomew’s Hospital, London EC1A 7BE, UK; 2. JJR Macleod Centre for
Diabetes, Endocrinology & Metabolism (Mac-DEM), Aberdeen Royal Infirmary, Foresterhill, Aberdeen
AB25 2ZP, UK; 3. Institute of Metabolism and Systems Research, School of Clinical and Experimental
Medicine, University of Birmingham, Wolfson Dr, Edgbaston, Birmingham B15 2TT, UK; 4. Dept
Endocrinology, The Christie NHS Foundation Trust, Wilmslow Rd, Manchester, M20 4BX, UK; 5.
Neurosciences and Mental Health Research Institute, School of Medicine, Cardiff University, Cardiff,
CF24 4HQ, UK; 6. Diabetes and Endocrine Centre, Royal Bournemouth Hospital, Castle Ln E,
Bournemouth, Dorset, BH7 7DW, UK; 7. Dept Endocrinology, University College London Hospital, 235
Euston Rd, London, NW1 2BU, UK; 8. Queen’s Hospital, Rom Valley Way, Romford, Essex, RM7 0AG,
UK; 9. Dept of Endocrinology, Leeds Centre for Diabetes & Endocrinology, St James’s University Hospital,
Leeds, LS9 7TF, UK; 10. Department of Endocrinology, Queen Elizabeth Hospital, University Hospitals
Birmingha, NHSFT, Edgbaston, Birmingham, B15 2TH, UK; 11. Imperial Centre for Endocrinology,
Imperial College Healthcare NHS Trust, London. W6 8RF, UK; 12. Department of Endocrinology, Royal
Devon & Exeter Hospital, University of Exeter Medical School, Exeter, EX2 4TP, UK; 13. Institute of
Cardiovascular Research, Royal Holloway, University of London (ICR2UL) & Ashford and St Peter’s NHS
Foundation Trust, Surrey, TW20 0EX, UK.; 14. Dept Cardiology, University Hospitals Birmingham NHS
Foundation Trust, Birmingham B15 2TH, UK
CONTEXT Uncertainty exists whether the long-term use of ergot-derived dopamine agonist (DA)
drugs for the treatmentofhyperprolactinemiamaybeassociatedwith clinically significant valvular
heart disease; and whether current regulatory authority guidelines for echocardiographic screen-
ing are clinically appropriate.
OBJECTIVE: To provide follow-up echocardiographic data on a previously described cohort of
patients treated with DA for lactotrope pituitary tumors; and to explore possible associations
between structural and functional valve abnormalities with the cumulative dose of drug used.
DESIGN:Follow-up echocardiographic data were collected from a proportion of our previously
reported cohort of patients; all had received continuous DA therapy for at least 2 years in the
intervening period. Studies were performed according to British Society of Echocardiography
minimum standards for adult transthoracic echocardiography. Generalised estimating equations
with backward selection were used to determine odds ratios of valvular heart abnormalities ac-
cording to tertiles of cumulative cabergoline dose, using the lowest tertile as the reference group.
SETTING: Thirteen centers of secondary/tertiary endocrine care across the United Kingdom.
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RESULTS: There were 192 patients (81 males; median age, 51 years; interquartile range [IQR],
42–62). Median (IQR) cumulative cabergoline doses at the first and second echocardiograms were
97mg (20–377) and 232mg (91–551) respectively. Median (IQR) duration of uninterrupted caber-
goline therapy between echocardiograms was 34months (24–42). No associations were observed
between cumulative doses of dopamine agonist used and the age-corrected prevalence of any
valvular abnormality.
CONCLUSION: This large UK follow-up study does not support a clinically significant association
between the use of DA for the treatment of hyperprolactinemia and cardiac valvulopathy.
Patients with lactotrope pituitary tumors who requiremedical therapy are typically treated with dopamine
agonists (DAs). Among the ergot-derivedDAs in common
use, cabergoline is most widely prescribed because of its
greater efficacy and better side-effect profile than bro-
mocriptine, although some physicians still favor the latter
drug for use in women attempting conception and for
those in established pregnancy who require treatment to
control tumor size.
Following the publication of a number of case reports,
cohort studies and case-controlled series describing the
association of short-term, intensive high dose cabergoline
therapy for Parkinson’s diseasewith cardiac valvulopathy
(1, 2, 2, 3), guidance was issued by various medicines
regulatory authorities recommending screening with
transthoracic echocardiography (TTE) for all patients
with hyperprolactinemic states onmaintenance treatment
with this class of drug (4).
Since then, a number of groups have contributed data
to the literature inorder toguidepractice in this area.Most
studies have reported TTE findings in modest numbers of
patients with prolactinomas and compared them with
healthy controls (5–7, 7–15).Wehavepreviously reported
TTE data from a large (747 patients), multicenter, cross-
sectional UK study of patients with hyperprolactinemia
treatedwithDAs (16). Patientswere divided into quartiles
according to cumulativeDAdose,with the lowest quartile
acting as the ‘reference group’ against which higher quar-
tiles of DA ‘exposure’ were compared (16). Here, longi-
tudinal TTE findings are reported in a proportion of those
patients, all ofwhomhad received continuousDA therapy
for at least 2 years in the intervening period.
Materials and Methods
Patients
All 28 centers participating in our original study were con-
tacted and invited to contribute data to this follow-up study.
Thirteen centers contributed anonymizeddata from192patients
(median age, 51 years; interquartile range [IQR], 42–62), of
which 81 were males. The remaining fifteen centers cited time
and/or local financial resource constraints as the reasons for not
participating in this follow-up study. Inclusion criteria for this
study were that all patients must have had two TTEs, separated
temporally by at least two years and that all patients should have
received uninterrupted cabergoline therapy between those two
studies. Demographic and clinical data collected previously was
cross-checked again for this study, included age, gender, dura-
tion of treatment, maintenance dose of drug, whether the tumor
was a microadenoma (10 mm) or macroadenoma (10 mm),
and the presence or absence of any previous cardiac history or
risk factors for cardiac disease (smoking, hypertension, diabetes
mellitus, hyperlipidemia, history of rheumatic fever). Cumula-
tive doses of cabergoline were calculated by multiplying the
weekly dose by the duration of therapy; this calculation was
repeated each time the patient’s dose was adjusted by the super-
visingphysicianandallowed the calculationof a total cumulative
cabergoline exposure dose.
Echocardiography
As in our previous study, all TTE examinations were per-
formed by fully-trained sonographers in accordance with the
British Society ofEchocardiographyminimumdataset for a stan-
dard adult transthoracic echocardiogram (17). Valve assessment
included evaluation of morphology (leaflet thickening, calcifi-
cation, mobility) and function of the mitral, aortic, pulmonary,
and tricuspid valves in multiple views. Two-dimensional imag-
ing was followed by color Doppler echocardiography after op-
timizing gain (to eliminate random speckle color from nonmov-
ing regions) andNyquist limit (50–60 cm/s) (18). Standard pulse
wave and continuous wave Doppler examinations were per-
formed. Valvular regurgitation was quantified as absent, mild,
moderate, or severe by integratingmultiple indices of severity (4,
19). As in our previous study, potentially clinically significant
valvular disease (morphological or functional)was considered to
be moderate or above.
Statistical Analysis
TTEparametersweredescribedusingmedians and IQRs.The
Wilcoxon signed rank test was used to compare parameters be-
tween the first and second studies. Generalized estimating equa-
tions, to take account of the repeated TTE measurements, were
used to determine univariate odds ratios (ORs) for moderate or
above abnormalities of any valve according to tertiles of caber-
goline dose and patient characteristics. Generalized estimating
equationswith backwards selectionwere used to determinemul-
tivariate ORs. ORs were also calculated for mild or above val-
vular abnormalities. Statistical significancewas taken asP .05.
All analyseswere performed in Stata version 13 (StataCorp,Col-
lege Station, Texas, USA).
The project was supported by the Clinical Endocrinology
Trust. Institutional review board permission was obtained at
each center.
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Results
Of the 192 patients, there were 88 (46%) with a microad-
enoma,93 (48)hadamacroadenomaand in the remainder
it was not specified by the referring physician. Median
(IQR) cumulative cabergoline doses at the time of the first
and second TTEs were 97 mg (20–377) and 232 mg (91–
551) respectively. Median (IQR) weekly cabergoline dose
was 0.5 mg (0.5–1.0). Median (IQR) duration of uninter-
rupted cabergoline therapy between the two studies was
34 months (24–42).
There were 11 echocardiographic abnormalities of
moderate severity at the time of the first TTE. Of these, 6
had become mild by the time of the second study, 4 were
unchanged and in 1 patient moderate tricuspid regurgita-
tionwas reported to have progressed to severe. Therewere
4 mild echocardiographic abnormalities at the first TTE
thathadbecomemoderateby the timeof the second (Table
1).More detailed information on the 9 echocardiographic
abnormalities of moderate or above severity at the second
study (in 7 patients) is also presented in Table 1.
Calculated ORs of any valvular abnormality (thicken-
ing, restricted movement, calcification, stenosis, regurgi-
tation, with and without the inclusion of mild lesions) by
tertile of exposure to DA are shown graphically in Table
2. No associations were observed between cumulative
doses of cabergoline and the age-corrected prevalence of
any valvular abnormality.ORswere not influenced by the
presence or absence of a cardiac history, previous rheu-
matic fever or any of the risk factors for heart disease and
no differences were observed when patients with mi-
croand macro-adenomas were analyzed separately.
Discussion
In this study we have performed detailed, follow-up TTE
in a large cohort of patientswith hyperprolactinemiawho,
in addition to being exposed toDA therapy before the first
examination, received uninterrupted treatment for at least
two years before the second. Compared to our previous
report, this cohort of patients contains a greater propor-
tion of men and patients classified as having a macroad-
Table 1. Details of 9 moderate or above valvular lesions in 7 patients at the time of the second echocardiogram,
together with details of cardiovascular (CV) risk factors, cumulative cabergoline (CAB) dose and other salient
echocardiographic features to indicate the clinical significance of the valvular lesions observed. AR – aortic
regurgitation; TR – tricuspid regurgitation; PR – pulmonary regurgitation; MR – mitral regurgitation; HTN –
hypertension;1Chol – hypercholesterolemia; IHD – ischaemic heart disease & LV/RV – left ventricle/right ventricle;
Mod – moderate; LVED/Svol – left ventricular end-diastolic/systolic volume; IVS – interventricular septal dimension in
diastole; PW – posterior wall thickness in diastole; RVID – right ventricular internal dimension in diastole; AV – aortic
valve; TR Vmax – maximum velocity of tricuspid regurgitation
Case Gender
Age
(yrs) Echo 1 Echo 2
Cumulative CAB dose at 2nd
echo (mg)
CV risk
factors Other echo features
1 Female 43 Mod TR Mod TR 761.4 None Normal RV size and function 1st
and 2nd echo
2 Male 80 Mod AR Mod AR 714.9 HTN Normal LV size and function 1st
and 2nd echo
1Chol LV IVS 1.4 cm PW 1.1 cm (1st
echo)
IHD LV IVS 1.9 cm PW 1.3 cm (2nd
echo)
3 Male 74 Mod TR; Mod MR; Mild PR Mild TR; Mod MR; Mod PR 1192.1 HTN Normal LV size and function 1st
and 2nd echo
Normal RV size and function 1st
and 2nd echo
4 Male 92 Mod AR; Mod TR Mod AR; Severe TR 354.6 IHD Normal LV size and function 1st
and 2nd echo
Severe RV dilatation 2nd echo
TR Vmax 2.8 m/s 2nd echo
5 Male 80 Mild MR Mod MR 2761.3 Smoker LV dilatation 1st and 2nd echo
HTN LVEDvol 196mls; LVESvol 125
mls (1st echo)
DM LVEDvol 175 mls; LVESvol 140
mls (2nd echo)
1Chol Normal mitral valve leaflet
morphology (1st echo)
IHD Diffuse mitral valve thickening (2nd
echo)
6 Female 52 Mild TR Mod TR 230.8 None Normal LV size and function 1st
and 2nd echo
RVID base 3.5 cm (1st echo)
RVID base 3.8 cm (2nd echo)
TR Vmax 2.1 m/s (1
st echo)
TR Vmax 3.3 m/s (2
nd echo)
7 Female 74 Mild MR Mod MR 1059.8 IHD Normal LV size and function 1st
and 2nd echo
Normal mitral valve leaflet
morphology
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enoma. This is likely to reflect the higher background re-
mission rate in women and of microadenomas such that
some of these originally reported patients will have dis-
continued DA at some stage in the intervening period and
not have been eligible for inclusion in this study. A patient
population enrichedwithmenandpatientswithmacroad-
enomas is a useful one to study as it contains those most
likely to need to continue DA therapy for a prolonged
period of time. These data do not suggest a clinically sig-
nificant effect of DA therapy at ‘endocrine doses’ on car-
diac valvular functionduringmedium-term follow-upand
provide further reassurance to physicians using this class
of drug for this clinical indication.
The background to the clinical question of the cardiac
safety of DA has been extensively documented and sum-
marized. Cabergoline binds to the same receptors (5-
HT2B) thatmediate carcinoidheartdisease, although there
is no direct relationship between plasma levels of 5-HT
andpresence of valvulopathy suggesting that other factors
may be required for the pathogenesis of valve dysfunction
(20).Althoughcardiac valvulopathymayoccur inpatients
withneurological disorders currently treatedwithdoses of
cabergoline up to 3 mg daily for more than 6 months (1),
many endocrine physicians experienced in the manage-
ment of pituitary disease were surprised by the various
regulatory authority recommendations for TTE surveil-
lance in patients with hyperprolactinemia. The doses in-
volved in the treatment of hyperprolactinemia are, typi-
cally, approximately 1/20th – 1/40th of those used in the
treatment of Parkinson’s disease. Most lactotrope pitu-
itary microadenomas occur in women, for whom either
spontaneous remission or intervening pregnancies dictate
that the drug is frequently prescribed for a limited period
of time. Even if women require prolonged use of caber-
goline for hyperprolactinemia, it is often possible to dis-
continue therapy at the time of the menopause. Our data
suggest that the current recommendations (exclusion of
cardiac valvulopathy before commencement of DA ther-
apy; secondTTE3–6months after starting treatment; and
serial examinations at 6- to 12-month intervals while DA
therapy is continued) are out of keeping with the risk of
developing clinically significant valve disease. Based on
estimates of the prevalence of lactotrope pituitary tumors,
such a surveillance program would require an estimated
90 000 extra TTEs per year in the United Kingdom (19) at
a time when both public and private healthcare providers
are seeking to ensure use of cardiovascular imaging is ap-
propriate (21). Nonfinancial implications, such as patient
anxiety and inconvenience, are harder to quantify.
The publication of data regarding valvulopathy in pa-
tients with Parkinson’s(1) came more than two decades
after the first clinical trials of DA agonist use in hyperp-
rolactinemia (22). There are major problems in designing
studies to address the issue of possible cardiac valvulopa-
Table 2. Odds ratio (OR) of any cardiac valvular abnormality (moderate or above and mild or above) by tertile of
cumulative cabergoline exposure. In each set of ORs the lowest tertile of cabergoline exposure serves as the reference
(ref) against which tertiles 2 and 3 are compared. *All ORs are age-adjusted.
Any valvular abnormality
moderate or above
Any valvular abnormality
mild or above
OR* (95% CI) p-value OR (95% CI) p-value
Cumulative cabergoline dose at
first echocardiogram (mg)
35 1 (ref) 1 (ref)
35–236 2.30 (0.51–10.31) 0.276 0.80 (0.45–1.42) 0.448
236 3.09 (0.75–12.74) 0.118 0.88 (0.50–1.56) 0.663
Cumulative cabergoline dose at
second echocardiogram (mg)
116 1 (ref) 1 (ref)
116–405 1.07 (0.25–4.53) 0.931 0.55 (0.31–0.97) 0.040
405 2.36 (0.66–8.49) 0.189 0.72 (0.40–1.29) 0.272
Cumulative cabergoline dose
between echocardiograms
(mg)
54 1 (ref) 1 (ref)
54–123 2.57 (0.58–11.44) 0.214 0.73 (0.42–1.29) 0.284
123 2.83 (0.63–12.74) 0.176 1.19 (0.67–2.12) 0.556
Months between
echocardiograms
28.3 1 (ref) 1 (ref)
28.3–40.5 2.15 (0.55–8.44) 0.274 1.62 (0.91–2.88) 0.102
40.5 3.28 (0.85–12.64) 0.085 1.03 (0.59–1.82) 0.914
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thy in patients taking ‘endocrine doses’. Withholding DA
therapy from patients with hyperprolactinemia (particu-
larly women wanting to conceive) in order to perform
controlled studieswould clearly beunethical; andanypos-
tulated cardiac effects ofDA therapy (positive or negative)
would be hard to separate from any secondary changes
that may occur as a consequence of normal gonadal ste-
roid levels being restored to previously hypogonadal pa-
tients. Further,with thepatentoncabergolinehavingdied,
large-scale multicenter phase IV studies in this area are
improbable. Most of the literature in this area therefore
comes from single-center studies of modest numbers of
DA-treated patients compared to age-matched healthy
controls. Most those studies have provided reassuring
data regarding valve function, with just three reports of
increased tricuspid regurgitation (moderate in one,mild in
two others) and an inconsistent relationship to the cumu-
lative dose of drug (5, 7, 8)
To our knowledge, this is the largest follow-up echo-
cardiographic study of hyperprolactinemic patients
treated with DA. Although the size is an obvious strength,
as in our previous study, an obvious weakness is the lack
of a true control group, with the lowest tertile of DA ex-
posure serving as our ‘surrogate control’. In an earlier
follow-up study, statistically significant increases in aortic
valve calcification were observed with DA therapy, al-
though these changes did not translate into any alterations
in valve function (7, 23). Moreover, while grading the
extent of valve calcification is an important factor in pre-
dicting outcome in AS (24), visual estimation on 2D echo-
cardiography is subjective andhas high interobserver vari-
ability (25). This could simply be that cardiac
valvulopathy develops over a prolonged time period and
that clinically significant functional changes (defined in
most studies as moderate severity or above) cannot be
detected over the timescales of the reported studies. It was
for this reason that we included an analysis based on ‘mild
or above severity’ as a statistically significant increase in
the prevalence of mild valvular abnormalities could pro-
vide preliminary evidence of developing clinically relevant
valvulopathy.We foundno evidence of an increase inmild
anatomical or functional valvulopathy with increasing
DA exposure.
Reassuring groupdata can sometimes conceal clinically
important effects in small numbers of patients. It is for this
reason that we present the details of the 9 moderate or
above echocardiographic abnormalities in 7 patients seen
at the second TTE; these cases illustrate some of the chal-
lenges of interpreting echocardiographic findings in this
context. The median age of the 7 patients was 74; all ex-
cept one patient was older than the median age of the
overall cohort. Although this may suggest the observed
abnormalities were age-related, this group of patients
were also heavily exposed to DA; all except one patient
had received a cumulative cabergoline dose above the me-
dian for the overall cohort. In case 5, for example, while
the risk factor profile anddocumentedhistory of IHDmay
well have been important factors in the progressive mitral
regurgitation, the appearance of thickening of the valve
leaflets is also compatible with DA therapy being etiolog-
ically contributory. Determining which echocardio-
graphic abnormalities carry clinical significance is alsodif-
ficult. Current echocardiography systems such as those
used in this study detect ‘physiological’ tricuspid regurgi-
tation in almost all subjects and ‘physiological’ mitral re-
gurgitation in more than half (26). While ‘trivial’ and
‘mild’ regurgitation are so common, it is also recognized
that significant reporter bias exists when information
about the use of DA in patients undergoing surveillance
TTE is provided to cardiac technicians (27). Moreover,
quantification, even when using recognized methodology
including vena contracta and proximal isovelocity surface
area, is only modestly reliable; interobserver agreement
for grading mitral regurgitation as severe or nonsevere is
only 0.28 between specialists working in academic hos-
pitals (28). In patients with less severe regurgitation, not
only will interobserver variability be higher but there may
well be physiological variation that will cause some
change in categorisation. It is not clear whether newer
imaging modalities such as cardiac magnetic resonance
imaging (MRI)will providemore accurate or reproducible
assessment of mild degrees of regurgitation (29).
In summary, this follow-up echocardiographic study
provides further, reassuring evidence that cardiac valvu-
lopathy is not a major clinical issue in patients with lac-
totrope pituitary adenomas treated with DA over this
timescale. Prospective, case-controlled studies of the size
and duration required formally to address this issue are
unlikely to be conducted, given their prohibitive cost and
logistical challenges. Although the design and duration of
the published studies cannot ‘exonerate’ DA of a possible
role in causing cardiac valvulopathy, we suggest that the
time is now appropriate for regulatory authorities to con-
sider revising the guidelines for surveillance echocardiog-
raphy in this group of patients.
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